Theodora Mistras was named Chief Financial Officer of Edwards Lifesciences Corp, effective May 29, 2026. As of November 6, 2026, Edwards Lifesciences Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 4, 2026 to August 28, 2026, naming 1 appointment (Form 8-K, May 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Edwards Lifesciences Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Edwards Lifesciences Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-04 to 2026-08-28. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Edwards Lifesciences Corp files it.
Also on the record for Edwards Lifesciences Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.54% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.5% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 3.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Edwards Lifesciences Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Edwards Lifesciences Corp and the records around it.
Edwards Lifesciences Corp elsewhere on the record
Companies that share a holder
- Wellington Management Group LLP also filed stake reports on 240 other companies: Hub Group, Inc. (Oct 2026), Latham Group, Inc. (Oct 2026), Redwood Trust, Inc. (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Edwards Lifesciences Corp
Get an email when Edwards Lifesciences Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Edwards Lifesciences Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Edwards Lifesciences Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Edwards Lifesciences Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-28 | Reported | not named in the filing | 8-K, 2026-08-28 | ||
| 2026-05-04 | In | Chief Financial Officer | 2026-05-29 | 8-K, 2026-05-04 |
Who leads Edwards Lifesciences Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Theodora Mistras, appointed, effective 2026-05-29 (filed 2026-05-04).
New leaders reset buying decisions — get the Full Report on Edwards Lifesciences Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Edwards Lifesciences Corp, with the record behind each one.
Find candidates like Chief Financial Officer at Edwards Lifesciences CorpEvery change, in the filing's words
Reported
The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation ("Edwards" or the "Company"), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027.
- A selection process will begin promptly to identify a successor, which is expected to result in a transition of duties during 2027.
Appointed: Theodora Mistras, Chief Financial Officer, effective 2026-05-29
On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the "Company"), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.
- Ms. Mistras, age 44, has served as Chief Financial Officer of Viatris, Inc. (NASDAQ: VTRS), a global pharmaceutical and healthcare corporation, since March 1, 2024.
- Prior to joining Viatris, Inc. as CFO-elect in January 2024, Ms. Mistras was Managing Director, Healthcare Investment Banking at Citigroup Global Markets from September 2019 to December 2023 and prior to that was Managing Director, Healthcare Investment Banking at Goldman Sachs, where she spent over 15 years in their investment banking healthcare group.
- In connection with her appointment as Corporate Vice President, Chief Financial Officer, Ms. Mistras and the Company entered into an Offer Letter on May 2, 2026 (the "Offer Letter").
- The Offer Letter does not provide for a specified term and provides for an at-will employment relationship.
- Pursuant to the Offer Letter, Ms. Mistras will receive a base salary at a rate of $925,000 annually and will be eligible to participate in the Edwards Lifesciences Incentive Plan (the "EIP") with a target annual bonus amount of not less than 100% of her then current annual base salary rate.
Tools for this story
Each opens in a new tab, filled in for Edwards Lifesciences Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.